LigBuilder V3: A Multi-Target de novo Drug Design Approach

With the rapid development of systems-based pharmacology and poly-pharmacology, method development for rational design of multi-target drugs has becoming urgent. In this paper, we present the first de novo multi-target drug design program LigBuilder V3, which can be used to design ligands to target...

Full description

Bibliographic Details
Main Authors: Yaxia Yuan, Jianfeng Pei, Luhua Lai
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Chemistry
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fchem.2020.00142/full
id doaj-9c7abdfd3b8444d0adcf5909b9a2d2a8
record_format Article
spelling doaj-9c7abdfd3b8444d0adcf5909b9a2d2a82020-11-25T00:34:40ZengFrontiers Media S.A.Frontiers in Chemistry2296-26462020-02-01810.3389/fchem.2020.00142508229LigBuilder V3: A Multi-Target de novo Drug Design ApproachYaxia Yuan0Jianfeng Pei1Luhua Lai2Luhua Lai3Luhua Lai4Beijing National Laboratory for Molecular Sciences, State Key Laboratory for Structural Chemistry of Unstable and Stable Species, College of Chemistry and Molecular Engineering, Peking University, Beijing, ChinaCenter for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, ChinaBeijing National Laboratory for Molecular Sciences, State Key Laboratory for Structural Chemistry of Unstable and Stable Species, College of Chemistry and Molecular Engineering, Peking University, Beijing, ChinaCenter for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, ChinaCenter for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, ChinaWith the rapid development of systems-based pharmacology and poly-pharmacology, method development for rational design of multi-target drugs has becoming urgent. In this paper, we present the first de novo multi-target drug design program LigBuilder V3, which can be used to design ligands to target multiple receptors, multiple binding sites of one receptor, or various conformations of one receptor. LigBuilder V3 is generally applicable in de novo multi-target drug design and optimization, especially for the design of concise ligands for protein targets with large difference in binding sites. To demonstrate the utility of LigBuilder V3, we have used it to design dual-functional inhibitors targeting HIV protease and HIV reverse transcriptase with three different strategy, including multi-target de novo design, multi-target growing, and multi-target linking. The designed compounds were computational validated by MM/GBSA binding free energy estimation as highly potential multi-target inhibitors for both HIV protease and HIV reverse transcriptase. The LigBuilder V3 program can be downloaded at “http://www.pkumdl.cn/ligbuilder3/”.https://www.frontiersin.org/article/10.3389/fchem.2020.00142/fullDe novo designMulti-target drug design (MTDD)multi-target drug optimizationDual-functional inhibitorsLigBuilder
collection DOAJ
language English
format Article
sources DOAJ
author Yaxia Yuan
Jianfeng Pei
Luhua Lai
Luhua Lai
Luhua Lai
spellingShingle Yaxia Yuan
Jianfeng Pei
Luhua Lai
Luhua Lai
Luhua Lai
LigBuilder V3: A Multi-Target de novo Drug Design Approach
Frontiers in Chemistry
De novo design
Multi-target drug design (MTDD)
multi-target drug optimization
Dual-functional inhibitors
LigBuilder
author_facet Yaxia Yuan
Jianfeng Pei
Luhua Lai
Luhua Lai
Luhua Lai
author_sort Yaxia Yuan
title LigBuilder V3: A Multi-Target de novo Drug Design Approach
title_short LigBuilder V3: A Multi-Target de novo Drug Design Approach
title_full LigBuilder V3: A Multi-Target de novo Drug Design Approach
title_fullStr LigBuilder V3: A Multi-Target de novo Drug Design Approach
title_full_unstemmed LigBuilder V3: A Multi-Target de novo Drug Design Approach
title_sort ligbuilder v3: a multi-target de novo drug design approach
publisher Frontiers Media S.A.
series Frontiers in Chemistry
issn 2296-2646
publishDate 2020-02-01
description With the rapid development of systems-based pharmacology and poly-pharmacology, method development for rational design of multi-target drugs has becoming urgent. In this paper, we present the first de novo multi-target drug design program LigBuilder V3, which can be used to design ligands to target multiple receptors, multiple binding sites of one receptor, or various conformations of one receptor. LigBuilder V3 is generally applicable in de novo multi-target drug design and optimization, especially for the design of concise ligands for protein targets with large difference in binding sites. To demonstrate the utility of LigBuilder V3, we have used it to design dual-functional inhibitors targeting HIV protease and HIV reverse transcriptase with three different strategy, including multi-target de novo design, multi-target growing, and multi-target linking. The designed compounds were computational validated by MM/GBSA binding free energy estimation as highly potential multi-target inhibitors for both HIV protease and HIV reverse transcriptase. The LigBuilder V3 program can be downloaded at “http://www.pkumdl.cn/ligbuilder3/”.
topic De novo design
Multi-target drug design (MTDD)
multi-target drug optimization
Dual-functional inhibitors
LigBuilder
url https://www.frontiersin.org/article/10.3389/fchem.2020.00142/full
work_keys_str_mv AT yaxiayuan ligbuilderv3amultitargetdenovodrugdesignapproach
AT jianfengpei ligbuilderv3amultitargetdenovodrugdesignapproach
AT luhualai ligbuilderv3amultitargetdenovodrugdesignapproach
AT luhualai ligbuilderv3amultitargetdenovodrugdesignapproach
AT luhualai ligbuilderv3amultitargetdenovodrugdesignapproach
_version_ 1725312260286447616